glp-1 constipation lawsuit in michigan law firm office Nutritional priorities to support GLP-1 therapy for obesity Pursuing a GLP-1 Drug – Food Companies Are Targeting Users

Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (surpass-3 MRI): A substudy of the randomised, open-label, parallel-group, phase 3 surpass-3 trial

Clinical trial data show that weight loss continues to accumulate for approximately 60 to 72 weeks after starting treatment, with the rate of loss gradually slowing as you approach a new equilibrium

Your gut microbiome is too important to leave to chance

Eat on a Schedule, Not When Hungry Your hunger cues are going to be completely unreliable this first week

Key findings: Prescribing trends Using a subset of Truveta Data, Truveta Research identified people who were prescribed a GLP-1 RA between January 01, 2019 and December 31, 2025

Nevertheless, analysts caution that drug manufacturing takes years to ramp up and capacity constraints will persist in the near term ( [12] ) ( [32] )